PEOPLE - Changes at Andaris (UK):
This article was originally published in Clinica
Andaris, a UK developer of in vivo imaging and therapeutic products, has appointed Dr Stuart Collinson of Glaxo Wellcome CEO. David Heath, Andaris' lead founder, has retired as chairman but remains a non-executive director and consultant to the UK company. Gordon Hall, previously managing director of Shield Diagnostics, joins as non-executive chairman.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.